Want to see SE:OSSD full AI Analyst Report?
Top Page
OssDsign AB
(OSSD)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr4.00
▲(0.50% Upside)
Action:Reiterated
Date:08/19/26
The score is held down primarily by weak financial performance (ongoing losses and continued cash burn, plus a TTM revenue pullback). Technicals also remain bearish with the stock trading below major moving averages and muted momentum. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Strong Gross Margins
Exceptionally high gross margins indicate a high-value product mix and provide substantial gross-profit capacity. This creates a durable foundation for eventual operating leverage if OssDsign can expand revenue and control operating costs.
Negative Factors
Persistent Operating Losses
OssDsign remains structurally unprofitable despite improving losses from earlier years. Persistent operating deficits show that current revenue is insufficient to cover the cost base, leaving profitability dependent on stronger growth or meaningful cost reductions.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Exceptionally high gross margins indicate a high-value product mix and provide substantial gross-profit capacity. This creates a durable foundation for eventual operating leverage if OssDsign can expand revenue and control operating costs.
Read all positive factors
OssDsign AB (OSSD) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr464.63M
Dividend YieldN/A
Average Volume (3M)297.02K
Price to Earnings (P/E)―
Beta (1Y)-0.53
Revenue Growth-2.61%
EPS Growth-0.28%
CountrySE
Employees35
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.45
Shares Outstanding110,625,916
10 Day Avg. Volume325,245
30 Day Avg. Volume297,022
Financial Highlights & Ratios
PEG Ratio3.08
Price to Book (P/B)4.04
Price to Sales (P/S)6.95
P/FCF Ratio-17.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)kr170.73M
OssDsign AB Business Overview & Revenue Model
Company Description
OssDsign AB (publ) specializes in the innovation, manufacturing, and distribution of advanced implant and material technologies crucial for bone regeneration. The company operates across a broad international market, including Sweden, Germany, the...
OssDsign AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 163.80M | 180.16M | 133.94M | 112.16M | 56.98M | 31.73M |
| Gross Profit | 154.13M | 173.47M | 127.75M | 83.64M | 45.13M | 20.84M |
| EBITDA | -52.24M | -44.30M | -45.31M | -122.02M | -89.41M | -79.97M |
| Net Income | -50.95M | -50.99M | -49.66M | -130.49M | -99.39M | -93.92M |
Balance Sheet | ||||||
| Total Assets | 367.68M | 397.87M | 307.42M | 356.39M | 339.50M | 343.99M |
| Cash, Cash Equivalents and Short-Term Investments | 152.53M | 191.35M | 100.86M | 165.94M | 124.65M | 151.37M |
| Total Debt | 935.00K | 1.37M | 1.97M | 3.15M | 13.60M | 14.13M |
| Total Liabilities | 79.81M | 87.84M | 93.36M | 105.26M | 91.39M | 81.26M |
| Stockholders Equity | 287.88M | 310.03M | 214.06M | 251.13M | 248.11M | 262.72M |
Cash Flow | ||||||
| Free Cash Flow | -65.91M | -71.43M | -63.04M | -94.03M | -89.36M | -89.84M |
| Operating Cash Flow | -52.94M | -64.03M | -62.38M | -93.91M | -89.23M | -89.78M |
| Investing Cash Flow | -16.33M | -7.40M | -657.00K | -124.00K | -129.00K | -51.85M |
| Financing Cash Flow | 9.04M | 163.18M | -2.46M | 135.40M | 61.84M | 243.43M |
OssDsign AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | kr1.22B | 24.37 | 14.08% | 0.26% | -0.27% | 93.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | kr1.03B | -94.72 | -2.58% | ― | 28.39% | -141.02% | |
52 Neutral | kr543.18M | -64.58 | -2.84% | ― | -13.72% | 52.47% | |
45 Neutral | kr1.09B | -30.61 | -3.99% | ― | -0.34% | 29.54% | |
44 Neutral | kr622.57M | -5.58 | -37.43% | ― | 27.40% | 26.07% | |
42 Neutral | kr464.63M | -9.28 | ― | ― | -2.61% | -0.28% |
* General Sector Average
SE:OSSD
OssDsign AB
3.96
-11.19
-73.88%
SE:PAX
Paxman AB
43.55
-31.05
-41.62%
SE:SEZI
Senzime AB
4.04
-2.41
-37.34%
SE:BACTI.B
Bactiguard Holding AB
15.20
-12.40
-44.93%
SE:CRAD.B
C-Rad AB Class B
35.80
2.60
7.84%
SE:SEDANA
Sedana Medical AB
10.36
-5.24
-33.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.